circulating levels of obesity-related markers and risk of renal cell carcinoma in the PLCO Cancer Screening Trial

Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6068, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI) plans to procure on a sole source basis with Jewish General Hospital 3755 Cote Ste Catherine Road Montreal, Quebec H3T 1E2 for circulating levels of obesity-related markers and risk of renal cell carcinoma in the PLCO Cancer Screening Trial. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The North American Industry Classification System code is 541380 and the business size standard is $12M. Period of performance is for twelve months from time of award. It has been determined that there is no opportunity to acquire green products or services under this contract. Obesity is a well-established risk factor for renal cell carcinoma (RCC). It has been estimated that excess body weight may account for over 40% of incident cases of RCC in the U.S. population, and that each 5 kg/m2 increase in body mass index (BMI) corresponds to a 24% and 34% increased risk of RCC among men and women, respectively. Despite clear epidemiologic evidence of an association between obesity and RCC, the specific biologic mechanisms underlying this association have not yet been determined. Hypothesized mechanisms of obesity-related carcinogenesis include: increased insulin resistance and chronic hyperinsulinemia; alterations in circulating levels of hormones and related binding proteins in the insulin-like growth factor (IGF) pathway; and altered expression of adipokines, hormones secreted by adipose tissue. Overall, the evidence of associations between IGF-1, IGFBP-3, adiponectin and RCC risk is intriguing and warrants further investigation. Because of the relatively small number of cases of RCC in a prospective analysis conducted in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC), particularly for the IGF analysis (N=100), and the composition of this cohort (restricted to Finnish male smokers), replication of these findings in another prospective cohort, such as the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial is critical to understanding the role of these obesity-related markers in the etiology of RCC. NCI also has the opportunity to extend findings from ATBC by evaluating RCC risk in relation to high molecular weight (HMW) adiponectin and the ratio of HMW adiponectin to total adiponectin. All previous assay work to measure adiponectin, leptin, IGF-1, and IGFBP-3 within the NCI ATBC and PLCO cohort studies has been conducted by Sir Mortimer B. Davis Jewish General Hospital. For scientific comparability, it is critical that the laboratory measurements of these analytes be carried out in the same laboratory. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on August 23, 2012. No electronic capability statements will be accepted (i.e. email or fax), an original and one copy must be sent to the NCI Office of Acquisitions at the address stated above. All questions must be in writing and can be faxed +1 (555) 000-0000 or emailed to Erin Breedlove, Contract Specialist at contact@example.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-120165-EB on all correspondence.